Loss of ERα and/or PgR expression in recurrent HR+ BC can result from the clonal selection of biologically heterogeneous primary or metastatic BC lesions during the course of ETs, i.e., under the selective pressure of reduced extracellular estrogens or the pharmacological inhibition of the ERα pathway (Figure 3) [81]. The gene discussed is ESR1; the disease is breast cancer.